A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL

  • End date
    Sep 10, 2025
  • participants needed
  • sponsor
    Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Updated on 10 July 2022
btk inhibitor


This is a Phase I/II, single arm, multi-center, open-label clinical trial of MS-553 in patients with CLL/SLL whose disease relapsed after or was refractory to at lease 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy) and who are indicated for treatment per IWCLL2018.

Condition Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Treatment MS-553
Clinical Study IdentifierNCT05272813
SponsorShenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Last Modified on10 July 2022


Yes No Not Sure

Inclusion Criteria

Age 18 years or older, male or female
Diagnosis of CLL/SLL per IWCLL2018 criteria
Patients with relapsed or refractory CLL/SLL who have failed at least 1 prior therapy (chemotherapy and/or targeted drug therapy, which must include BTK inhibitor therapy), are indicated for treatment per IWCLL2018
Measurable lesions detected by contrast-enhanced computed tomography (CT): at least one lymph node with a maximum axis of more than 1.5 cm and one measurable vertical dimension
WHO/ECOG performance status of 0 to 2
Patients with an estimated survival of more than 3 months

Exclusion Criteria

Biopsy-proven and pathologically confirmed current or past transformation to Richter's syndrome
Patients with active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura
Patients who have received any of the following treatments within 14 days prior to the first dose
Major surgery
Glucocorticoids (at a dose equal to or greater than 20 mg/day prednisone or equivalent), unless used by inhalation, topical or intraarticular route, or unless necessary for premedication before and after iodinated contrast dye. After discussion with the Sponsor, steroid therapy at high doses for an extended period may be allowed under the following circumstances
Treatment of autoimmune hemolysis or autoimmune thrombocytopenia associated with CLL/SLL
Short-term (within 14 days) use to treat inactive infections of diseases unrelated to CLL/SLL (e.g. arthritis, asthma), which results in acute exacerbation, including steroid dose modifications required for adrenal insufficiency
Cytotoxic chemotherapy or biologic therapy, excepting BCR pathway kinase
inhibitors for which a washout of 24 hours prior to the first dose is
Toxicity from prior anti-tumor therapy (chemotherapy, radiotherapy, or biotherapy) did
not restore to ≤ Grade 1 (except for alopecia); atrial fibrillation from prior
treatment with BTK inhibitors did not restore to ≤ Grade 2
Central nervous system (CNS) leukemia or lymphoma, including a history of asymptomatic, previously treated CNS disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note